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Abstract 
Introduction: Radiofrequency echographic multi-spectrometry (REMS) is a recently introduced non-ionising technology employed in 
the evaluation of osteoporosis. The aim of our study was to compare bone mineral density (BMD) in acromegaly patients and healthy 
controls by performing novel REMS densitometry. The second objective was to analyse the correlation between results of REMS and 
classical dual-energy X-ray absorptiometry (DXA) in acromegaly patients.
Material and methods: We enrolled 33 patients with acromegaly (AG) and 24 controls (CG). The acromegaly patients were divided into 
two subgroups: well-controlled acromegaly (WCA) and surgery-cured acromegaly (SCA). REMS was performed in all participants, while 
DXA was performed only in the acromegaly group. IGF-I and GH levels were measured in acromegaly patients.
Results: Bone mineral density of the lumbar spine (LS) and the femoral neck (FN) obtained from REMS did not reveal significant dif-
ferences between AG, CG, WCA, and SCA. Similarly, there were no significant differences in BMD measured by DXA at the LS and at 
the FN between WCA and SCA. Significant positive correlations between IGF-I concentrations and BMD obtained from both REMS and 
DXA were detected in the AG and WCA. In the AG and WCA, there were positive correlations between T-scores and LS BMD obtained 
from both methods. 
Conclusions: Radiofrequency echographic multi-spectrometry is a potential method in assessment of bone status in acromegaly. Further 
studies with participation of active disease patients are needed. (Endokrynol Pol 2020; 71 (6): 524–531)
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Introduction
Acromegaly is a rare disease characterised by elevated 
levels of growth hormone (GH) and insulin-like growth 
factor I (IGF-I) mainly due to pituitary adenoma [1]. An 
excess amount of these hormones leads to a lot of sys-
temic complications including secondary osteoporosis 
and vertebral fractures [2, 3]. Growth hormone and 
IGF-I are anabolic hormones responsible for enhanced 
bone formation and achievement of peak bone mass. In 
acromegaly patients an increased bone turnover as well 
as an imbalance between bone resorption and forma-
tion were described [4–7]. Growth hormone and IGF-
I affect the cortical and trabecular bone differently [4, 8]. 
The impact on cortical bone is complex — the excess of 
GH and IGF-I promotes development of cortical thick-
ness, but at the same time it contributes to increased 
cortical porosity [9]. What is more, a negative impact 
on trabecular tissue was observed [2, 10]. Impaired 
structure of trabecular bone was reported not only in 
active disease but also after achieving remission [11, 
12]. Reduced trabecular thickness, increased trabecular 
separation, and cortical porosity could be reasons for 
increased fracture risk in acromegaly [2, 7, 12, 13]. Frac-
tures with coexisting pain and immobility are among 
the most important problems deteriorating the quality 
of life in patients with acromegaly [14].
Nowadays dual-energy X-ray absorptiometry (DXA) 
remains a gold standard for bone mineral density 
(BMD) measurement in diagnostics of osteoporosis. In 
acromegaly, BMD has some limitations. Increased bone 
size and spine deformities are factors affecting BMD 
values [15, 16]. Bone mineral density does not have 
adequate potential to reflect bone microarchitecture; 
therefore, it is not appropriate for bone quality assess-
ment [7]. Co-existing diseases also influence BMD. 
Hypogonadism, which often accompanies acromegaly, 
may contribute to lower BMD [8]. In turn, diabetes 
is associated with paradoxically high BMD despite 
increased risk of fractures [2]. Osteoarthritis may also 
lead to an overestimation of BMD [7]. Moreover, the 
presence of fractures and calcifications disturb the ac-
curacy of DXA. It has been highlighted that patients 
with acromegaly are at risk of fractures despite normal 
or high BMD values [2,7]. On account of limitations of 
BMD measured by DXA, some alternative methods for 
Małgorzata Rolla, Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wybrzeże Ludwika  
Pasteura 4, 50–367 Wrocław, Poland, fax: (+48) 71 327 09 57; e-mail: malgorzata.rolla@student.umed.wroc.pl
525










obtained from all individual participants. In the acromegaly group 
(AG) we enrolled patients (mean age 59.1 ± 9.8 years) with diagnosis 
of acromegaly based on clinical features and laboratory results (el-
evated IGF-I and GH not suppressed during oral glucose tolerance 
test), with long-term observation of controlled or cured disease 
(IGF-I < 1.3 upper limit of normal was a criterion of well-controlled 
or cured disease). Patients were divided into two subgroups: 20 
patients with controlled disease during treatment with long-acting 
somatostatin analogues were assigned to the well-controlled ac-
romegaly subgroup (WCA), and 13 patients were assigned to the 
surgically cured acromegaly subgroup (SCA). To the control group 
(CG) we recruited age-matched subjects without clinical features 
of acromegaly or diagnosis of other secondary osteoporosis-related 
diseases in their medical history. 
Questionnaires concerning coexisting diseases, history of fractures, 
surgeries, and current pharmacology treatment were taken from 
all participants of the study. Fractures defined as fragility fractures 
[22, 23] were observed in five patients from the AG group and in no 
patients from the CG group. Traumatic fractures were recognised in 
two acromegaly patients and in six controls. Additionally, some par-
ticipants of the study had recommendations to take vitamin D and 
calcium: nine acromegaly patients and three controls took vitamin 
D (1000–4000 U daily); four patients with acromegaly and two con-
trols took calcium (500–1000 mg daily). Moreover, two patients with 
acromegaly were treated with bisphosphonates (ibandronic acid). 
In CG one woman received hormone replacement therapy. Among 
the acromegaly group 11 patients had pituitary insufficiency at least 
affecting one axis (seven thyrotropic, five corticotropic, and three 
gonadotropic). None of the patients with hypogonadism received 
hormone replacement therapy. In addition, nine acromegaly pa-
tients and two controls suffered from diabetes mellitus.
The analyses were performed based on the division into subgroups. 
The first classification was used to analyse the differences between 
a group of acromegaly patients (AG) and controls (CG). The second 
division was done on the basis of the status of the disease (WCA; 
SCA) and CG.
The study was approved by the local ethical committee. Informed 
consent was obtained from all participants.
Laboratory assays
Blood samples were obtained from acromegaly patients. Serum 
GH and IGF-I were measured with a chemiluminescent immuno-
metric method (Immulite 2000, Siemens Healthcare Diagnostics, 
USA). Analytical sensitivity was 0.01 ng/mL for GH and 20.0 ng/mL 
for IGF-I.
Densitometry
Radiofrequency echographic multi-spectrometry examinations 
were performed in the acromegaly and control groups. Ultrasound 
scans of lumbar spine and femoral neck were performed employ-
ing EchoS (Echolight, Italy). Bone mineral density, T-score, and 
Z-score values were obtained by system calculation and compared 
with a dedicated database. Densitometry with dual-energy X-ray 
absorptiometry (DXA) was performed in the acromegaly group. 
Bone mineral density was measured at the lumbar spine (L1–L4) 
and femoral neck using dual-energy X-ray absorptiometry (DXA, 
Hologic — Discovery QDR Series) equipped with reference values 
based on NHANES III. According to WHO definitions, osteoporosis 
was diagnosed if the T-score was ≤ –2.5, and low bone density if 
> –2.5 and < –1.0. 
Statistical analysis
Statistical analysis was performed using R for Windows, version 
3.5. Differences between groups were analysed with the Wilcoxon 
rank sum and Kruskal-Wallis rank sum tests. Associations between 
variables were tested by Spearman correlation analysis. P values 
less than 0.05 were considered statistically significant.
bone status assessment such as quantitative computed 
tomography (QCT) [15,17], quantitative ultrasound 
(QUS) [18–20], and impact microindentation [11] have 
been investigated. Further search for diagnostic tools, 
especially to assess status of bone microarchitecture, 
is needed.
Radiofrequency echographic multi-spectrometry 
(REMS) is a recently introduced non-ionising technol-
ogy employed in the evaluation of osteoporosis. The 
method is based on the analysis of radiofrequency (RF) 
signals acquired after conversion ultrasound spectra 
obtained during echographic scan of lumbar vertebrae 
or femoral neck. During the examination the operator 
visualises the target bones employing a 3.5-MHz convex 
probe placed at the abdomen or hip. The software auto-
matically detects regions of interest (ROI) by comparing 
obtained images to matrices of the RF signals. Then ROI 
RF signals are compared with reference models [age-, 
sex-, body mass index (BMI)-, and site-matched] from 
the dedicated database and matched to pathological or 
normal condition. It is important to note that the system 
distinguishes spectra of trabecular bone and of cortical 
bone and cartilage. The analysed spectrum is classified 
in the Osteoporosis Score and then transformed into 
a BMD value by linear equations. T- and Z-score are 
calculated based on National Health and Nutrition 
Examination Survey (NHANES) database. Before the 
examination no special preparation is needed, the 
procedure is short (up to two minutes), and can be 
performed in any setting because the densitometer is 
mobile. REMS technology was proposed as a new tool 
in screening of primary osteoporosis. In a multicentre 
study involving 1914 women, the new technique was 
described as precise, and the results were comparable 
with those obtained from DXA [21]. So far, no research 
assessing the usefulness of the method was performed 
in evaluating endocrine related osteoporosis.
The aim of our study was to compare BMD and 
T-scores evaluated by novel REMS densitometry of 
the lumbar spine and femoral neck in a group of acro-
megaly patients and healthy controls. Second objective 
was to analyse the correlation between results of REMS 
and DXA densitometries in acromegaly patients. To 
our knowledge, this is the first study comparing these 
techniques in acromegaly.
Material and methods 
Patient population
We enrolled 33 patients with acromegaly (25 women and 8 men) 
and 24 healthy subjects as a control group (CG) (17 women and 
7 men). All participants were recruited from the Department of 
Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical 
University. Approval for the study was obtained from the ethics 
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Results
The general characteristics of the groups are presented 
in Table 1. Anthropometric parameters (weight, height, 
BMI), age, menopause age, and years after menopause 
did not differ significantly between the analysed 
groups. There were no significant differences in IGF-I 
and GH concentrations between WCA and SCA sub-
groups.
Bone mineral density, T-scores, and Z-scores of the 
lumbar spine (LS) and the femoral neck (FN) obtained 
from REMS did not reveal significant differences between 
acromegaly patients and the controls (Tab. 2 and Tab. 3). 
Similarly, we did not observe significant differences in T-
scores, Z-scores, and BMD measured by REMS and DXA at 
the LS and at the FN between WCA and SCA subgroups. 
The number of patients with diagnosis of osteoporo-
sis and low bone density varied depending on the used 
Table 1. Characteristics of acromegaly patients and the control group
AG CG WCA SCA
Mdn q1 q3 Mdn q1 q3 Mdn q1 q3 Mdn q1 q3
No. 33 24 20 13
Sex: F (M) 25 (8) 17 (7) 13 (7) 12 (1)
Age (yrs) 60.0 53.0 65.0 55.5 51.0 64.3 61.5 54.5 67.5 58.0 48.0 64.0
Weight [kg] 80.0 70.0 95.0 77.0 62.8 82.8 82.5 75.0 95.5 76.0 69.0 94.0
BMI [kg/m2] 29.0 26.4 31.4 27.9 25.0 29.8 29.2 27.3 31.3 28.6 25.7 33.3
Menopause age 
(yrs) 50.0 45.5 52.0 49.0 44.5 55.0 48.5 45.8 52.3 50.0 46.5 51.5
Years after 
menopause (yrs) 6.0 0.0 14.0 0.0 0.0 8.75 4.5 0.0 14.0 6.0 0.0 14.0
IGF-I [ng/mL] 152.0 124.0 189.0 NA NA NA 153.5 117.3 196.8 141.0 133.0 166.0
GH [ng/mL] 1.0 0.4 1.9 NA NA NA 1.5 0.6 2.1 0.4 0.2 1.1
AG — acromegaly group; CG — control group; WCA — well-controlled acromegaly; SCA — surgery-cured acromegaly; Mdn — median; q1 — first quartile;  
q3 — third quartile; BMI — body mass index; IGF-I — insulin-like growth factor I; GH — growth hormone
Table 2. Comparison of radiofrequency echographic multi-spectrometry (REMS) and dual-energy X-ray absorptiometry (DXA) 
results of the lumbar spine (median)
  REMS L1–L4 DXA L1–L4
BMD p T-score p Z-score p BMD p T-score p Z-score p
AG 0.977 0.69 a –0.6 0.66 a 0.7 0.25 a 1.042 – 0.0 – 0.9 –
CG 0.977 0.69 a –0.7 0.66 a 0.7 0.25 a – – – – – –
WCA 1.037 0.70 b –0.3 0.65 b 1.1 0.07 b 1.069 0.51c 0.0 0.30 c 0.9 0.08 c
SCA 0.971 0.70 b –0.7 0.65 b 0.4 0.07 b 0.971 0.51c –0.7 0.30 c 0.9 0.08 c
BMD — bone mineral density; AG — acromegaly group; CG — control group; WCA — well-controlled acromegaly; SCA — surgery-cured acromegaly;  
a — comparison between AG and CG; b — comparison between WCA, SCA and CG; c — comparison between WCA and SCA
Table 3. Comparison of radiofrequency echographic multi-spectrometry (REMS) and dual-energy X-ray absorptiometry (DXA) 
results of the femoral neck (median)
REMS femoral neck DXA femoral neck
BMD p T-score p Z-score p BMD p T-score p Z-score p
AG 0.841 0.23 a –0.2 0.24 a 0.8 0.11 a 0.879 – –0.1 – 1.2 –
CG 0.777 0.23 a –0.7 0.24 a 0.6 0.11 a – – – – – –
WCA 0.848 0.49 b –0.1 0.49 b 1.0 0.22 b 0.871 0.51 c –0.2 0.30 c 1.0 0.08 c
SCA 0.748 0.49 b –0.9 0.49 b 0.6 0.22 b 0.879 0.51 c 0.3 0.30 c 1.4 0.08 c
AG — acromegaly group; CG — control group; WCA — well-controlled acromegaly; SCA — surgery-cured acromegaly; a — comparison between AG and CG; 
b — comparison between WCA, SCA and CG; c — comparison between WCA and SCA
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densitometry technique. These results are presented 
in Table 4. The results of REMS revealed osteoporosis 
at LS and FN in 3.7 and 3.3%, respectively, of AG and 
in none of the participants of CG. However low bone 
density was observed more often in CG than in AG: 37.5 
vs. 29.6 % at LS and 30.0 vs. 26.7% at FN. 
In the AG group, and also in the WCA and SCA 
subgroups, we analysed correlations between IGF-I and 
GH concentrations and BMD measured by REMS and 
DXA densitometries (Tab. 5). The study revealed signifi-
cant positive correlations between IGF-I concentrations 
and LS BMD and FN BMD obtained from both REMS 
and DXA methods in the AG and WCA groups. There 
was no correlation between GH concentration and 
BMD for REMS or for DXA method.
We also checked correlations between BMD and 
anthropometric parameters. LS BMD (REMS technique) 
correlated positively with height and weight in the AG, 
CG, and WCA groups. Similarly, positive correlations 
were found for LS BMD by DXA in the AG and WCA 
groups. At femoral neck, for the REMS method, we 
also observed positive correlations with height and 
weight in the AG, CG, and WCA groups. FN BMD 
(DXA technique) correlated positively with weight in 
the AG and WCA groups, and with height, but only in 
the AG group. 
A negative correlation between LS BMD measured 
by REMS and age was noted in the AG and WCA 
groups, but not in the CG group. For the DXA method, 
this association was observed for LS BMD in the AG 
and SCA groups. At the FN area a negative correlation 
between BMD (REMS method) and age was revealed 
only in the WCA group. Moreover, there were negative 
correlations between FN BMD (DXA method) and age 
in the AG and WCA groups. Additionally, we noted sig-
nificant negative correlations between BMD and years 
after menopause in the AG and WCA groups, inde-
pendently of the method used. What is more, a similar 
correlation, but only for LS area, was found in the CG 
(REMS method) and in the SCA (DXA method) groups. 
In the AG and in the WCA groups, we found statisti-
cally significant positive correlations between T-scores 
obtained from REMS and from DXA at LS and FN ar-
eas (Fig. 1). They were observed between LS T-scores 
(r = 0.482, p = 0.011) and FN (r = 0.431; p = 0.018) in 
the AG group. In WCA positive correlations were re-
vealed between LS T-scores (r = 0.537, p = 0.032) and 
FN (r = 0.528, p = 0.020).
Likewise, for LS BMD positive correlations between 
methods were revealed in the AG and WCA groups 
(r = 0.546, p = 0.003 and r = 0.544, p = 0.032, respec-
tively). There was no correlation for FN BMD assessed 
by REMS and by DXA techniques. 
Discussion
Patients with acromegaly have an increased risk of 
fracture, which might be correlated with poor quality 
of bone. Prevalence of vertebral fractures is three- to 
eight-fold higher than in the general population [3]. 
In our study 15% of acromegaly patients experienced 
osteoporotic fracture, while this was not observed in the 
control group. Although screening for osteoporosis is 
recommended in acromegaly [3, 24] and DXA remains 
a gold standard, vertebral fractures may be present in 
patients with normal or slightly decreased BMD, which 
makes BMD obtained from DXA an inadequate fracture 
predictor [8, 20, 25]. Using of FRAX has not been vali-
dated in patients with acromegaly [26]. Nevertheless, 
we do not have other useful tools to detect bone dam-
age and estimate real risk for fractures. As we showed 
in a previous study, usage of FRAX could be functional 
in combination with other tools such as TBS [27]. The 
early diagnosis of acromegaly and investigations for 
new markers as well as for new diagnostic methods for 
assessing the risk of osteoporotic fractures are very im-
portant to improve care of acromegaly patients. REMS 
technology is one of the promising new methods pro-
posed in the screening of osteoporosis [21, 28]. In our 
study we analysed results of densitometry performed 
with novel REMS method and traditional DXA in acro-
Table 4. Comparison of bone mineral density (BMD) (median), diagnosis of osteoporosis and low bone density (% of the 
group) obtained by radiofrequency echographic multi-spectrometry (REMS) and dual-energy X-ray absorptiometry (DXA)
BMD Osteoporosis Low bone density
Lumbar spine Femoral neck Lumbar spine Femoral neck Lumbar spine Femoral neck
REMS DXA REMS DXA REMS DXA REMS DXA REMS DXA REMS DXA
AG 0.977 1.042 0.841 0.879 3.7 12.1 3.3 0.0 29.6 24.2 26.7 27.3
CG 0.977 – 0.777 – 0.0 – 0.0 – 37.5 – 30.0 –
WCA 1.037 1.069 0.848 0.871 6.3 10.0 5.3 0.0 31.3 35.0 26.3 35.0
SCA 0.971 0.971 0.748 0.879 0.0 15.4 0.0 0.0 27.3 7.7 27.3 15.4

































































































































































































































































































































































































































































































































































































































































































































































































































megaly patients. To our knowledge, this is the first study 
comparing these techniques in acromegaly. 
Bone mineral density is a parameter measured in 
both DXA and REMS techniques. In our study we found 
no statistically significant differences in BMD among 
the groups in each method. This observation is consis-
tent with some previous reports. Tuzcu et al. found no 
differences for T-score and BMD values obtained from 
DXA between the active acromegaly and control groups 
[29]. Among patients with active, controlled, and cured 
disease Madeira et al. also did not observe differences 
for BMD value [30]. Also comparison between the active 
acromegaly, GH deficiency, and control groups did not 
reveal BMD distinctions [10]. In our study, there were 
no differences for BMD by DXA between the WCA and 
SCA subgroups. What is more, the study did not prove 
differences for BMD obtained from REMS between the 
AG and CG. We did not evaluate bone microarchitec-
ture, but we imply that BMD in acromegaly may be 
overestimated due to higher cortical bone thickness 
[9]. In acromegaly a high prevalence of osteoarthritis 
might be a factor which disrupts DXA accuracy. Bone 
degenerations, presence of osteophytes and calcifica-
tions contribute to higher results of BMD, especially in 
the lumbar area [8]. Preliminary research has reported 
that the REMS method should be able to automatically 
remove signals that arise from artifacts like calcifications 
and osteophytes [31], which makes REMS a potentially 
beneficial method in bone assessment in acromegaly. 
Further investigations and evaluation of BMD by REMS 
among patients with active acromegaly and osteoar-
thritis are necessary.
We obtained a positive correlation between IGF-I 
and BMD in both methods in the AG and WCA 
groups. This association may reflect the anabolic effect 
of IGF-I on bones. Nevertheless, such a correlation 
was not observed for GH concentration, which may 
indicate a complex effect of the GH-IGF-I axis on bone 
status. Consistent results were reported in Tuzcu’s study 
[29]. Moreover acromegaly treatment was reported to 
increase BMD, but decrease trabecular bone score (TBS), 
which is a promising marker of bone quality [2, 5]. Posi-
tive correlation between IGF-I and BMD support the 
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Figure 1. Correlations between radiofrequency echographic multi-spectrometry (REMS) and dual-energy X-ray absorptiometry (DXA) 
in the acromegaly patients (AG). A. Correlation between REMS and DXA lumbar spine bone mineral density (BMD); B. Correlation 
between REMS and DXA lumbar spine T-scores; C. Correlation between REMS and DXA femoral neck BMD; D. Correlation between 
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tissue. The influence of IGF-I on BMD in acromegaly 
patients masks impairment of bone quality in this group.
Bone mineral density correlated positively with height 
and weight in both methods in all groups except for 
SCA (in this subgroup, the only correlation was between 
FN BMD measured by REMS and weight). Low BMI is 
a known factor contributing to higher risk of osteopo-
rosis [32]. In both acromegaly and control groups the 
median BMI was diagnostic of overweight. Bone mineral 
density within normal limits in the acromegaly group 
might be related to high BMI values. Lack of typical 
correlations for height and weight in the SCA subgroup 
are quite surprising observations. We speculate that 
this discrepancy might be due to heterogeneity of the 
group. Factors that might contribute to these results are 
divergence in length of active disease, length of period 
from operation, age of disease appearance, and gonadal 
status. Also, the small number of participants in the 
group may influence these results.
Old age and early menopause are negative predic-
tors for BMD. Age is one of the dominant determinants 
affecting bone loss in the general population as well as 
in acromegaly patients [5]. We found a negative correla-
tion between BMD and age in both methods, but it was 
better expressed in the DXA method. Bone loss increases 
after menopause due to lower levels of oestrogens [33]. 
Negative correlation between years after menopause 
and BMD was more pronounced in the REMS method 
than in DXA. However, in the SCA group we did not 
observe any correlation between results obtained from 
REMS and years after menopause, but there was nega-
tive correlation between LS BMD measured by DXA. 
Insufficiency of gonadotropic axis may be a coexisting 
factor implicating low bone density in acromegaly [34]. 
In our study three patients had gonadal axis insuf-
ficiency. Among them, only one patient had low bone 
density of lumbar area diagnosed by DXA method. 
REMS accuracy
In the recent multicentre study REMS and DXA examina-
tions were performed in 1914 postmenopausal women 
[21]. Sensitivity, specificity, and accuracy of REMS com-
pared to DXA were analysed. The study revealed high 
positive correlation between T-scores measured in REMS 
and DXA both in lumbar and femoral neck areas. Diag-
nostic concordance between the two methods was 88.8% 
for lumbar spine and 88.2% for femoral neck. A high posi-
tive correlation between the two techniques was observed 
for lumbar area (r = 0.94; p < 0.001) and for femoral neck 
(r = 0.93; p < 0.001). In the research of 358 females with 
normal BMI, Casciaro et al. compared DXA and REMS 
densitometry in lumbar area [35]. They received 83% cor-
responding diagnosis. Moreover, previous single-centre 
studies also proved good accuracy between REMS and 
DXA results [36, 37]. In our study positive correlations 
between DXA and REMS lumbar and femoral T-scores 
were observed in AG and also in WCA but not in the 
SCA group. The correlations that we obtained are weaker 
than reported in previous studies, but many factors could 
contribute to these results. First of all, in previous research 
the study groups contained postmenopausal women, 
while in our study we investigated the group of patients 
at risk of secondary osteoporosis related to acromegaly. 
DXA, as already mentioned, is not an ideal method in 
the evaluation of bone quality in the acromegaly popula-
tion, so a flimsier association between results obtained by 
REMS and DXA may indicate better accuracy of REMS in 
screening of osteoporosis in this group. Further investiga-
tion to bear out this hypothesis is needed. We observed 
a positive correlation between LS BMD but not between 
FN BMD values. Hypothetically, this discrepancy might 
be due to different composition of spine and hip. Verte-
brae contain high amounts of trabecular tissue, which is 
a target in REMS analysis. Also, joint degeneration may 
contribute to these results because, as mentioned earlier, 
the REMS method should eliminate artefacts related to 
degenerations. Conversaro et al. also proved that results 
of measured BMD are repeatable and reproducible be-
tween interoperates, and the accuracy of the method does 
not depend on the experience of the operator [36]. From 
our experience, obtaining good quality echo scans of the 
hip area is more difficult and takes more time, even for 
an experienced operator.
Limitations
There are some limitations to this study. First, the 
sample size of the group of acromegaly patients was 
small, and the results of this study should be analysed 
in a larger group. Secondly, we did not enrol patients 
with active disease. Moreover, we did not perform DXA 
in the control group, so we could not compare results of 
REMS and DXA densitometries in controls and results 
of DXA between acromegaly patients and the control 
group. Also, we did not perform objective methods to 
evaluate fractures. The number of declared fractures 
was too small to perform statistical analysis, and there 
is a possibility of underestimation due to the probability 
of asymptomatic fractures. Finally, various duration of 
the disease, different dosage, and time span of therapy 
with somatostatin analogues, as well as lack of consider-
ation of vitamin D and calcium taking in the statistical 
analysis may influence the results of this study.
Conclusions
In conclusion, our study for the first time compared 
REMS densitometry with traditional DXA in acro-
megaly. The obtained outcomes did not clearly establish 
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whether REMS is a better technique for the evaluation 
of bone status in acromegaly; nevertheless, further stud-
ies are needed to evaluate the usefulness of REMS and 
its potential advantages compared to other methods 
in acromegaly patients. An investigation comparing 
REMS parameters with objective markers of resorption 
is required to determine whether this new technique 
could be a practical tool in bone turnover evaluation. 
Methods that can accurately and noninvasively assess 
bone quality are needed, especially in endocrine dis-
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